GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK GSK0.31%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

GSK shares have set a fresh low for the year, falling 49p to 1402p even though its core earnings figure of 49.7p a share beat ...

GSK GSK1.94%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

(Bloomberg) -- GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was ...

Seeking Alpha analyst and Investing Group leader, Manika Premsingh believes the worst is now behind GSK, adding that even though there is risk to core EPS growth of forecasts 10-12% for the full ...

GSK has also taken the opportunity to throw out some of research products that were not producing results. Development of a PI3kb inhibitor, GSK2636771, has been terminated as part of the R&D rethink.

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK to pay $70 million to settle whistleblower ... A drug currently sold under the name Zantac 360 uses a different active ingredient and contains no ranitidine. Sign up here.